Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

First Albany Keeps 'Buy' on Xoma

First Albany reiterates buy on Xoma (XOMA).

Analyst David Webber says an FDA advisory committee gave a positive review of Raptiva for moderate-to-severe plaque psoriasis. He believes the committee's unanimous vote for approval supports the likelihood Raptiva will be approved on or before the Oct. 27, 2003 FDA action date, with a cautionary but not harmful label.

Webber says the implications the of panel discussion are in line with his estimate that Raptiva will gain a 15% to 20% share of the market for biological treatments for psoriasis in 2007, translating into $600 million in expected sales that year. He upped his $9 target to $10.

blog comments powered by Disqus